12:00 AM
 | 
Oct 25, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SMART Anti-CD3 antibody: Began Phase II testing

Protein Design Labs Inc. (PDLI), Fremont, Calif.
Product: SMART Anti-CD3 antibody
Business: Transplant
Therapeutic category: Antibody, Immune suppression
Target: CD3
Description: Humanized antibody...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >